Grid AI Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • GRDX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $3.17
  • (As of Friday Closing)

Grid AI General Information

Description

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Contact Information

Website
www.grid-ai.com
Formerly Known As
First Wave Bio, AzurRx BioPharma, Entero Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 91 George Street
  • Edinburgh
  • Scotland, United Kingdom
Primary Industry
Business/Productivity Software
Other Industries
Application Software
Other Energy Services
Stock Exchange
NAS
Corporate Office
  • 91 George Street
  • Edinburgh
  • Scotland, United Kingdom

Grid AI Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Grid AI Stock Performance

As of 20-Nov-2026, Grid AI’s stock price is $3.17. Its current market cap is $32.4M with 10.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.17 $3.45 $1.87 - $6.93 $32.4M 10.3M 122K -$4.24

Grid AI Financials Summary

As of 30-Sep-2026, Grid AI has a trailing 12-month revenue of $198K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 35,472 81,189 64,431 (226)
Revenue 198 36 0 0
EBITDA (20,744) (5,574) (15,571) (15,746)
Net Income (22,165) (6,393) (18,059) (15,795)
Total Assets 38,057 48,552 85,410 6,883
Total Debt 1,979 2,264 141 827
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Grid AI Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Grid AI‘s full profile, request access.

Request a free trial

Grid AI Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company
Business/Productivity Software
Edinburgh, United Kingdom
2 As of 2025

Florham Park, NJ
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Grid AI Competitors (5)

One of Grid AI’s 5 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
MetaVia (Biotechnology) Formerly VC-backed Cambridge, MA
Alcresta Therapeutics Private Equity-Backed Waltham, MA
Union Therapeutics Venture Capital-Backed Hellerup, Denmark
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 5 competitors. Get the full list »

Grid AI Patents

Grid AI Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024119044-A2 Adrulipase compositions Inactive 01-Dec-2022
WO-2024119044-A3 Adrulipase compositions Inactive 01-Dec-2022
WO-2023163883-A1 Compositions and methods for treating pouchitis Inactive 22-Feb-2022
CA-3241068-A1 Lipase formulations and methods thereof Pending 16-Dec-2021
EP-4448741-A2 Lipase formulations and methods thereof Inactive 16-Dec-2021 C12N9/20
To view Grid AI’s complete patent history, request access »

Grid AI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grid AI Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Grid AI‘s full profile, request access.

Request a free trial

Grid AI Acquisitions (4)

Grid AI’s most recent deal was a Merger/Acquisition with Pronghorn Resources. The deal was made on 13-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pronghorn Resources 13-Nov-2026 Merger/Acquisition Energy Production
Grid AI(Business/Productivity Software) 30-Sep-2025 Merger/Acquisition Business/Productivity Software
ImmunogenX 13-Mar-2024 Merger/Acquisition Drug Discovery
AzurRx BioPharma 22-Sep-2021 Merger/Acquisition Drug Discovery
To view Grid AI’s complete acquisitions history, request access »

Grid AI ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Grid AI’s complete esg history, request access »

Grid AI Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Grid AI(Business/Productivity Software) Edinburgh, United Kingdom 2022
First Wave BioPharma (Niclosamide Program) Boca Raton, FL

Grid AI FAQs

  • When was Grid AI founded?

    Grid AI was founded in 2014.

  • Where is Grid AI headquartered?

    Grid AI is headquartered in Edinburgh, United Kingdom.

  • What is the size of Grid AI?

    Grid AI has 2 total employees.

  • What industry is Grid AI in?

    Grid AI’s primary industry is Business/Productivity Software.

  • Is Grid AI a private or public company?

    Grid AI is a Public company.

  • What is Grid AI’s stock symbol?

    The ticker symbol for Grid AI is GRDX.

  • What is the current stock price of Grid AI?

    As of 20-Nov-2026 the stock price of Grid AI is $3.17.

  • What is the current market cap of Grid AI?

    The current market capitalization of Grid AI is $32.4M.

  • What is Grid AI’s current revenue?

    The trailing twelve month revenue for Grid AI is $198K.

  • Who are Grid AI’s competitors?

    Phathom Pharmaceuticals, MetaVia (Biotechnology), Alcresta Therapeutics, Union Therapeutics, and Vedanta Biosciences are competitors of Grid AI.

  • What is Grid AI’s annual earnings per share (EPS)?

    Grid AI’s EPS for 12 months was -$4.24.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process